Many of the current approaches to cancer immunotherapy aim to exploit and enhance the natural T cell response against cancer. However, these treatment modalities may fall short of their potential due to the elimination of self-tumor antigen specific T cells from the immune repertoire to guard against autoimmunity. To investigate how the precursory frequency of self-antigen specific T cells shapes therapeutic outcome, our lab developed a model system in which the precursor number of T cells specific for a self/melanoma antigen could be manipulated in mice bearing melanoma tumors through the adoptive transfer of tumor specific T cells. Using this model we had previously determined that bringing the frequency of CD8+ T cells within or sligh...
There have been great advances in clinical immunotherapies against cancer over the past two decades....
Mutant tumor antigens have recently emerged as major targets of endogenous tumor-specific T cells. V...
Adoptive immunotherapy with autologous T lymphocytes transduced with anti-tumour antigen-specific T ...
Immunotherapy treatments have been a growing trend for treatment cancer since 2012 with the first cl...
Tumor antigen-specific CD4(+) T cells generally orchestrate and regulate immune cells to provide imm...
Tumor antigen-specific CD4(+) T cells generally orchestrate and regulate immune cells to provide imm...
AbstractRecent studies have identified new melanoma antigens that are recognised by CD4+ T cells. An...
Immune checkpoint inhibition represents a promising approach for multiple malignancies. Why successf...
Tumors express a wide variety of both mutated and nonmutated Ags. Whether these tumor Ags are broad...
Therapeutic vaccinations against cancer are still largely ineffective. Major caveats are inefficient...
Depletion of CD4+ cells using an anti-CD4 monoclonal antibody (anti-CD4 mAb) induces the expansion o...
Immune responses involve coordination across cell types and tissues. However, studies in cancer immu...
Immune checkpoint blockade results in T cell antitumor responses but most patients fail to respond. ...
This review presents key advances in combining T cell receptor (TCR) gene transfer to redirect T-cel...
Immunotherapy has become a standard treatment in many cancers and it is based on three main therapeu...
There have been great advances in clinical immunotherapies against cancer over the past two decades....
Mutant tumor antigens have recently emerged as major targets of endogenous tumor-specific T cells. V...
Adoptive immunotherapy with autologous T lymphocytes transduced with anti-tumour antigen-specific T ...
Immunotherapy treatments have been a growing trend for treatment cancer since 2012 with the first cl...
Tumor antigen-specific CD4(+) T cells generally orchestrate and regulate immune cells to provide imm...
Tumor antigen-specific CD4(+) T cells generally orchestrate and regulate immune cells to provide imm...
AbstractRecent studies have identified new melanoma antigens that are recognised by CD4+ T cells. An...
Immune checkpoint inhibition represents a promising approach for multiple malignancies. Why successf...
Tumors express a wide variety of both mutated and nonmutated Ags. Whether these tumor Ags are broad...
Therapeutic vaccinations against cancer are still largely ineffective. Major caveats are inefficient...
Depletion of CD4+ cells using an anti-CD4 monoclonal antibody (anti-CD4 mAb) induces the expansion o...
Immune responses involve coordination across cell types and tissues. However, studies in cancer immu...
Immune checkpoint blockade results in T cell antitumor responses but most patients fail to respond. ...
This review presents key advances in combining T cell receptor (TCR) gene transfer to redirect T-cel...
Immunotherapy has become a standard treatment in many cancers and it is based on three main therapeu...
There have been great advances in clinical immunotherapies against cancer over the past two decades....
Mutant tumor antigens have recently emerged as major targets of endogenous tumor-specific T cells. V...
Adoptive immunotherapy with autologous T lymphocytes transduced with anti-tumour antigen-specific T ...